This study identified nonpregnant adults with at least one outpatient encounter and serum creatinine assessment, focusing on ...

FDA approval of MIPLYFFATM and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra ...

Fitness coach Lizzy High has shared the simple lifestyle changes she made to her routine in a bid to lose weight and tone up, ...

Results: A ≥ 101% increment ... adjusted odds ratio of 2.66 (95% CI: 1.00–7.21). Patients in the ≥ 101% increment group had a higher mean serum creatinine level with respect to their ...

Star Domantas Sabonis was just one of 17 NBA players to play in all 82 games last season. He credits his durability, in part, to a meticulously-crafted diet. Sabonis outlined his diet in a recent ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, ...

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

Egypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights.

Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...